Molecular diagnostic test for cancer

A method of predicting response of an individual to, and treating an individual with, a DNA-damage therapeutic agent, comprising:

• a. measuring expression levels of at least five biomarkers in a test sample of cancer cells obtained from the individual, wherein the at least five biomarkers are selected from the biomarkers in Table 2B;
• b. deriving a combined test score that captures the expression levels;
• c. providing a threshold score comprising information correlating the test score and responsiveness to a DNA-damage therapeutic agent;
• wherein the individual is predicted to respond to a DNA-damage therapeutic agent when the test score exceeds the threshold score;
• and
• d. treating the individual that is so predicted to respond with a DNA-damage therapeutic agent.

A method of treating an individual predicted to respond to a modulator of DNA-damage-related immune signalling, comprising treating the individual with the modulator of DNA-damage-related immune signalling, wherein the individual has been predicted to respond to the modulator of DNA-damage-related immune signalling prior to treatment when a combined test score exceeds a threshold score, wherein the combined test score determination has been done by a method comprising:

• a. measuring expression levels of at least five biomarkers in a test sample of cancer cells obtained from the individual, wherein the at least five biomarkers are selected from the biomarkers in Table 2B;
• b. deriving a combined test score that captures the expression levels;
• and
• c. providing a threshold score comprising information correlating the test score and responsiveness to the modulator of DNA-damage-related immune signalling;
• wherein the individual is predicted to respond to the modulator of DNA-damage-related immune signalling when the test score exceeds the threshold score.

A method of predicting response of an individual to, and treating an individual with, a DNA-damage therapeutic agent, comprising:

• a. measuring expression levels of at least two biomarkers in a test sample of cancer cells obtained from the individual, wherein at least one biomarker is selected from the group consisting of CXCL10, IDO1, and APOL3;
• b. deriving a combined test score that captures the expression levels;
• c. providing a threshold score comprising information correlating the test score and responsiveness to a DNA-damage therapeutic agent;
• wherein the individual is predicted to respond to a DNA-damage therapeutic agent when the test score exceeds the threshold score;
• and
• d. treating the individual that is so predicted to respond with a DNA-damage therapeutic agent.